MedTrace Logo

REsponsible roLl-out of E-heAlth Through Systematic Evaluation - Heart Failure Study

NCT05654961 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 6480

Last updated 2022-12-16

No results posted yet for this study

Summary

Telemedicine is gradually becoming accepted in heart failure (HF) management. Meta-analyses show a positive effect of telemedicine on hospital admission, length of stay, mortality, and costs. However, the magnitude of the effect is heterogeneous because of the variety in the HF population using telemedicine, components of telemedicine, and variety in considered costs. Despite the lack of clear guidance how to implement telemedicine within routine HF management, implementation of telemedicine is advocated by payers, private companies, and patient organizations.

In this nationwide study the investigators aim to identify in which subgroup of HF patients telemedicine is (cost-)effective, and which intervention components of telemedicine are most (cost-)effective.

Conditions

Interventions

OTHER

Use of telemedicine

Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Folkert W. Asselbergs, MD, PhD · UMC Utrecht

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05654961 on ClinicalTrials.gov